Cargando…
Efficacy of erlotinib in NSCLC harboring rare EGFR extracellular domain mutation (T263P) and common mutations: Case report and literature review
The epidermal growth factor receptor (EGFR) typically contains an extracellular domain (ECD), a transmembrane (TM) domain, and an intracellular kinase (KD) domain. ECD mutations of EGFR in NSCLC may affect its normal function and intrinsic resistance to tyrosine kinase inhibitors (TKIs) and the effe...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9539819/ https://www.ncbi.nlm.nih.gov/pubmed/36212397 http://dx.doi.org/10.3389/fonc.2022.954026 |
_version_ | 1784803574326231040 |
---|---|
author | Wang, Qian Wang, Yong Zhang, Xinwei Fang, Chen Qian, Xiaoying Li, Yong |
author_facet | Wang, Qian Wang, Yong Zhang, Xinwei Fang, Chen Qian, Xiaoying Li, Yong |
author_sort | Wang, Qian |
collection | PubMed |
description | The epidermal growth factor receptor (EGFR) typically contains an extracellular domain (ECD), a transmembrane (TM) domain, and an intracellular kinase (KD) domain. ECD mutations of EGFR in NSCLC may affect its normal function and intrinsic resistance to tyrosine kinase inhibitors (TKIs) and the effectiveness of drugs for these patients is unsatisfactory. Recently, we found an EGFR T263P mutation located at the ECD, which has never been reported in Chinese non-small cell lung cancer (NSCLC). Hence, we reported that a patient with advanced lung adenocarcinoma harboring the EGFR T263P mutation, L858R mutation and MET amplification was resistant to osimertinib but significantly benefited from erlotinib and capmatinib treatment. This patient achieved a partial response and had progression-free survival (PFS) for more than 19 months. In summary, we are the first researchers to report in detail on a Chinese patient carrying the T263P mutation and summarize all the ECD mutations in NSCLC. We believe this finding will enlighten us to treat patients with EGFR ECD mutations and more patients deserve further study. |
format | Online Article Text |
id | pubmed-9539819 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95398192022-10-08 Efficacy of erlotinib in NSCLC harboring rare EGFR extracellular domain mutation (T263P) and common mutations: Case report and literature review Wang, Qian Wang, Yong Zhang, Xinwei Fang, Chen Qian, Xiaoying Li, Yong Front Oncol Oncology The epidermal growth factor receptor (EGFR) typically contains an extracellular domain (ECD), a transmembrane (TM) domain, and an intracellular kinase (KD) domain. ECD mutations of EGFR in NSCLC may affect its normal function and intrinsic resistance to tyrosine kinase inhibitors (TKIs) and the effectiveness of drugs for these patients is unsatisfactory. Recently, we found an EGFR T263P mutation located at the ECD, which has never been reported in Chinese non-small cell lung cancer (NSCLC). Hence, we reported that a patient with advanced lung adenocarcinoma harboring the EGFR T263P mutation, L858R mutation and MET amplification was resistant to osimertinib but significantly benefited from erlotinib and capmatinib treatment. This patient achieved a partial response and had progression-free survival (PFS) for more than 19 months. In summary, we are the first researchers to report in detail on a Chinese patient carrying the T263P mutation and summarize all the ECD mutations in NSCLC. We believe this finding will enlighten us to treat patients with EGFR ECD mutations and more patients deserve further study. Frontiers Media S.A. 2022-09-23 /pmc/articles/PMC9539819/ /pubmed/36212397 http://dx.doi.org/10.3389/fonc.2022.954026 Text en Copyright © 2022 Wang, Wang, Zhang, Fang, Qian and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Wang, Qian Wang, Yong Zhang, Xinwei Fang, Chen Qian, Xiaoying Li, Yong Efficacy of erlotinib in NSCLC harboring rare EGFR extracellular domain mutation (T263P) and common mutations: Case report and literature review |
title | Efficacy of erlotinib in NSCLC harboring rare EGFR extracellular domain mutation (T263P) and common mutations: Case report and literature review |
title_full | Efficacy of erlotinib in NSCLC harboring rare EGFR extracellular domain mutation (T263P) and common mutations: Case report and literature review |
title_fullStr | Efficacy of erlotinib in NSCLC harboring rare EGFR extracellular domain mutation (T263P) and common mutations: Case report and literature review |
title_full_unstemmed | Efficacy of erlotinib in NSCLC harboring rare EGFR extracellular domain mutation (T263P) and common mutations: Case report and literature review |
title_short | Efficacy of erlotinib in NSCLC harboring rare EGFR extracellular domain mutation (T263P) and common mutations: Case report and literature review |
title_sort | efficacy of erlotinib in nsclc harboring rare egfr extracellular domain mutation (t263p) and common mutations: case report and literature review |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9539819/ https://www.ncbi.nlm.nih.gov/pubmed/36212397 http://dx.doi.org/10.3389/fonc.2022.954026 |
work_keys_str_mv | AT wangqian efficacyoferlotinibinnsclcharboringrareegfrextracellulardomainmutationt263pandcommonmutationscasereportandliteraturereview AT wangyong efficacyoferlotinibinnsclcharboringrareegfrextracellulardomainmutationt263pandcommonmutationscasereportandliteraturereview AT zhangxinwei efficacyoferlotinibinnsclcharboringrareegfrextracellulardomainmutationt263pandcommonmutationscasereportandliteraturereview AT fangchen efficacyoferlotinibinnsclcharboringrareegfrextracellulardomainmutationt263pandcommonmutationscasereportandliteraturereview AT qianxiaoying efficacyoferlotinibinnsclcharboringrareegfrextracellulardomainmutationt263pandcommonmutationscasereportandliteraturereview AT liyong efficacyoferlotinibinnsclcharboringrareegfrextracellulardomainmutationt263pandcommonmutationscasereportandliteraturereview |